see the NHS orlistat page for eligibility and guidance), or GLP-1-based therapies such as semaglutide 2.4 mg (Wegovy), which has received MHRA approval and a NICE Technology Appraisal recommendation (NICE TA875) for use in adults with a BMI of 35 kg/m or above (or 3034.9 kg/m in certain circumstances) alongside at least one weight-related comorbidity, when used within a specialist weight management service Enquire about clinical trial eligibility , if you are interested in accessing investigational medicines through a regulated research pathway your GP or specialist can advise, and you can search for trials via the NIHR 'Be Part of Research' website or ClinicalTrials.gov Discuss realistic expectations , as even the most effective weight loss medicines work best alongside dietary changes, increased physical activity, and behavioural support Your GP can refer you to a specialist weight management service if appropriate
The medication is fine
However, no large-scale clinical investigations have shown that biotin supplements promote hair growth
Choline kinases: Enzymatic activity, involvement in cancer and other diseases, inhibitors
GLP-1 medications are contraindicated for people with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
We reserve the right to modify our courses at any time without notice